Multiple evidence has highlighted an upregulation of the PD1/PDL1 pathway in AML and a correlation with poor overall survival, adverse-risk mutations and karyotype anomalies, and a higher relapse rate [107,108,109,110]. The gene discussed is PDCD1; the disease is acute myeloid leukemia.